-

Bio-Rad to Participate in Fireside Chat During the 40th Annual J.P. Morgan Healthcare Conference on January 11

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO; Andrew Last, Executive Vice President and COO; and Ilan Daskal, Executive Vice President and CFO will participate in a virtual Fireside Chat during the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, at 1:30 PM (PST).

A link to the live webcast is available in the Investor Relations area of our website at bio-rad.com.

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology and pharmaceutical companies, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 7,800 employees worldwide. Bio-Rad had revenues exceeding $2.5 billion in 2020. For more information, please visit bio-rad.com.

Contacts

Investor Contact:
Bio-Rad Laboratories, Inc.
Edward Chung, Vice President, Investor Relations
510-741-6104
ir@bio-rad.com

Bio-Rad Laboratories, Inc.

NYSE:BIO

Release Versions

Contacts

Investor Contact:
Bio-Rad Laboratories, Inc.
Edward Chung, Vice President, Investor Relations
510-741-6104
ir@bio-rad.com

More News From Bio-Rad Laboratories, Inc.

Bio-Rad Reports Third-Quarter 2026 Financial Results

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the third quarter ended September 30, 2026. Norman Schwartz, Bio-Rad’s Chief Executive Officer, stated: “Our third-quarter results reflect the steady progress we have been driving. We returned to currency-neutral revenue growth, led by Clinical Diagnostics and strong demand for our Droplet Digital™...

Bio-Rad to Participate in Fireside Chat During UBS Global Healthcare Conference

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Financial Officer, Roop K. Lakkaraju, will participate in a fireside chat event during the UBS Global Healthcare Conference on Tuesday, November 10, 2026, at 8:00 AM Eastern Time. A live webcast and subsequent replay of the event will be available in the Investor Relations section of Bio-Rad’s website at i...

Bio-Rad to Report Third-Quarter 2026 Financial Results on Wednesday, November 4, 2026

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the third quarter of 2026 on Wednesday, November 4, 2026, following the close of the market. Management will discuss these results in a conference call scheduled for 2:00 PM Pacific Time (5:00 PM Eastern Time) that day.To participate, dial (800) 715-9871 within the U.S. or (646) 307-1963 outside the...
Back to Newsroom